2cd73426-figure-01 (2cd73426 Figure 01)
Chemical structure of Levetiracetam showing a pyrrolidone ring bonded to an ethyl group and an amide substitution.*
Levetiracetam
Product Images NDC 53808-0602
9 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-0602). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
2cd73426-figure-02 (2cd73426 Figure 02)
A bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis shows the percentage of patients from 0% to 45%. Bars indicate increased patient percentages with higher Levetiracetam doses compared to placebo.*
2cd73426-figure-03 (2cd73426 Figure 03)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart shows patient response rates with Placebo at 6.3%, Levetiracetam 1000 mg/day at 20.8%, and Levetiracetam 2000 mg/day at 35.2%.*
2cd73426-figure-04 (2cd73426 Figure 04)
A bar chart comparing the percentage of patients between two groups: a placebo group (N=104) at 14.4% and a Levetiracetam 3000 mg/day group (N=180) at 39.4%. The y-axis represents the percentage of patients, and the x-axis lists the treatment groups.*
2cd73426-figure-05 (2cd73426 Figure 05)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Levetiracetam group shows 44.6% patients, while the Placebo group shows 19.6% patients. The vertical axis represents the percentage of patients.*
2cd73426-figure-06 (2cd73426 Figure 06)
A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The chart shows 45.2% for Placebo and 72.2% for Levetiracetam, with the y-axis labeled as percentage of patients ranging from 0% to 100%.*
2cd73426-figure-07 (2cd73426 Figure 07)
Mathematical formula showing how to calculate total daily dose in mL/day for Levetiracetam, using daily dose in mg/kg/day, patient weight in kg, and the concentration of 100 mg/mL.*
2cd73426-figure-08 (2cd73426 Figure 08)
An illustration of the formula to calculate creatinine clearance (CLcr), showing the relationship between age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor for female patients. The formula is used to estimate renal function.*
500 mg Label (Levetiracetam Chamber)
Label for Levetiracetam 500 mg tablets showing product name, strength, dosage form, lot number, expiration date, and labeler as State of Florida DOH Central Pharmacy, Tallahassee, FL. Includes a barcode and UPC number. Marked as Rx only.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
